A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors

Inclusion Criteria

- Eligibility Criteria

Inclusion Criteria

- Patients must have histologically or cytologically confirmed diagnosis of solid
tumor. The diagnosis should be confirmed by the Laboratory of Pathology, NIH.

- Patients must have disease that is not amenable to potentially curative resection.

- Disease must be amenable to biopsy, and patients must be willing to undergo tumor
biopsies.

- Patients must have failed at least one line of prior therapy for metastatic disease
or have a disease for which no standard curative therapy exists. Prior
anti-angiogenic therapy is allowed.

- Age >=18 years. Because no dosing or adverse event data are currently available on
the use of EZN-2968 in patients < 18 years of age, children are excluded from this
study but will be eligible for future pediatric trials, if applicable.

- Life expectancy of greater than 3 months.

- ECOG performance status 0-2 (Karnofsky >=60%).

- Patients must have normal organ and marrow function as defined below:

absolute neutrophil count >=1,500/mcL

platelets >=100,000/mcL

total bilirubin <= 1.5 X ULN

AST/ALT <= 2.5 X institutional ULN

creatinine less than or equal to 1.5 x upper limit of normal

OR

creatinine clearance (measured) greater than or equal to 60 mL/minute for patients with
creatinine levels > 1.5 times upper limit of normal

INR <= 1.4

PTT <= 40 seconds unless due to lupus anticoagulant

- Urine protein should be screened by urine analysis for urine protein:creatinine (UPC)
ratio. For UPC ratio > 1, 24-hour urine protein should be obtained and the level
should be < 500 mg for patient enrollment.

- The effects of EZN-2968 on the developing human fetus are unknown. For this reason,
women of childbearing potential and men must agree to use adequate contraception
(abstinence; female use of hormonal methods, or barrier methods of birth control;
male use of a condom) prior to study entry, for the duration of study participation,
and for 6 months after completion of study. Because there is a risk for adverse
events in nursing infants secondary to treatment of the mother with EZN- 2968,
breastfeeding should be discontinued while the patient is on this trial and for

30 days after completion of treatment on this trial. Should a woman become pregnant
or suspect she is pregnant while participating in this study, she should inform her
treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

- Willingness to undergo tumor biopsies for research purposes.

Exclusion Criteria

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events to eligibility levels (by performance status and
laboratory criteria outlined above) due to agents administered more than 4 weeks
earlier. Patients may have received investigational agent(s) as part of a Phase 0
study (also referred to as an early Phase I study or pre-Phase I study where a
sub-therapeutic dose of drug is administered) at the PI's discretion, up to 2 weeks
prior to study entry.

- Patients may not be receiving any other investigational agents.

- Patients with active brain metastases will be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse
events. Patients whose brain metastatic disease status remains stable for >= 3 months
after treatment of the brain metastases without steroids or antiseizure medications
may be enrolled at the discretion of the principal investigator.

- Patients requiring therapeutic anticoagulation.

- Hypertension not controlled by medical therapy (hypertension defined as systolic
blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical
management).

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to EZN-2968.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements. A history of hepatitis is allowed if, following consultation with
Liver Diseases Branch, it is felt to be clinically stable.

- Pregnant women are excluded from this study because EZN-2968 has the potential for
teratogenic or abortifacient effects. Because there is an unknown but potential risk
for adverse events in nursing infants secondary to treatment of the mother with
EZN-2968, breastfeeding should be discontinued if the mother is treated with
EZN-2968.

- HIV-positive patients on combination antiretroviral therapy are ineligible because of
the potential for pharmacokinetic interactions with EZN-2968.

- Patients with surgical non-healing wounds. Patients with other non-healing wounds
will be evaluated and included at the PI's discretion if considered minor.